trial

A Positron Emission Tomography (PET) Study to Evaluate Dopamine D2 and D3 Receptor Occupancy by SIPI6398

NCTId NCT07626034
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Not Yet Recruiting
Enrollment 9 (estimated)
Sponsored by Shanghai Zhongze Therapeutics Co., Ltd.
Primary completion 2027-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Not Yet Recruiting
Enrollment
9 (estimated)
Study type
Interventional
Allocation
Non Randomized
Model
Sequential
Masking
None
Start
2026-08
Primary completion
2027-10
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
SIPI6398 Tablets

Sponsors

Shanghai Zhongze Therapeutics Co., Ltd.Lead Sponsor
Yale UniversityCollaborator

Sites

0 total

Linked catalysts

1
A Positron Emission Tomography (PET) Study to Evaluate Dopamine D2 and D3 Recept — primary completion2027-10

Facts & assertions

4 sourced
Enrollment
9
Phase
PHASE1,PHASE2
Primary Completion Date
2027-10
Status
NOT_YET_RECRUITING
relationships
The graph out of here
drug
SIPI6398 Tablets
drug
lead_sponsor
Shanghai Zhongze Therapeutics Co., Ltd.
company
collaborator
Yale University
company
indication
Schizophrenia
indication
Schizophrenia Disorder
indication